Access to and Utilization of Endocrine Therapy Among Breast Cancer Survivors in Botswana
JCO Global Oncology · 2024
DOI: 10.1200/go.24.00180 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Global Oncology, 2024. Verfasst von James R Wester und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA. Hauptthemen laut MEDLINE: Breast Neoplasms, Cancer Survivors, Antineoplastic Agents, Hormonal, Health Services Accessibility. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCI NIH HHS, FIC NIH HHS.
Abstract (Originalsprache)
PURPOSE Breast cancer (BC) is the most common female cancer worldwide, and the burden is increasing across sub-Saharan Africa. For women with hormone receptor–positive (HR+) cancers, endocrine therapy (ET) taken for 5-10 years can reduce the risk of recurrence by half. We explored experiences with ET and barriers to utilization among survivors in Botswana. METHODS We recruited women with nonmetastatic disease from a survivorship cohort who had undergone mastectomy within 1-5 years for semi-structured interviews to explore experiences with treatment. This thematic content analysis focused on ET, so the sample included women with HR+ cancer who should have received ET and HR− women who reported taking ET. RESULTS We analyzed interviews with 19 women (mean age 54 years, 42% stage I/II, 58% stage III). Three key themes were identified: (1) limited provider counseling, (2) challenges refilling prescriptions at public pharmacies, and (3) high medication and transportation costs associated with private pharmacies. Subthemes included immunohistochemistry result communication, lack of knowledge, frequent public pharmacy stockouts, inconvenient prescription refill policies, and medication switching and discontinuation, especially among participants with low socioeconomic positions (SEPs). Women's persistence, SEP, and financial support facilitated refills. Although some experienced side effects, they were not a common reason for discontinuation. CONCLUSION BC survivors in Botswana face multilevel barriers to accessing and adhering to ET. Provider and health system improvements are needed to effectively communicate ET importance and increase access to consistently available and affordable medication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA.
- Center for Cancer Health Equity, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.
- Botswana Harvard Health Partnership, Princess Marina Hospital, Gaborone, Botswana.
- Department of Surgery, University of Botswana, Gaborone, Botswana.
- Rutgers Global Health Institute, New Brunswick, NJ.
- Department of Internal Medicine, University of Botswana, Gaborone, Botswana.
ORCID-Profile: James R Wester, Rachel B Wagner, Nkhabe Chinyepi, Tara M Friebel-Klingner, Peter Vuylsteke, Shahin Lockman, Scott Dryden-Peterson, Racquel E Kohler
Förderung
- NIAID NIH HHS
- NCI NIH HHS
- FIC NIH HHS
Zitieren
APA
Wester, J. R., Wagner, R. B., Motladiile, B., Nkele, I., Chinyepi, N., Makhema, M. J., Friebel-Klingner, T. M., Vuylsteke, P., Lockman, S., Dryden-Peterson, S., & Kohler, R. E. (2024). Access to and Utilization of Endocrine Therapy Among Breast Cancer Survivors in Botswana. JCO Global Oncology. https://doi.org/10.1200/go.24.00180
Vancouver
Wester JR, Wagner RB, Motladiile B, Nkele I, Chinyepi N, Makhema MJ, et al. Access to and Utilization of Endocrine Therapy Among Breast Cancer Survivors in Botswana. JCO Global Oncology. 2024. doi:10.1200/go.24.00180
BibTeX
@article{Wester2024,
author = {Wester, James R and Wagner, Rachel B and Motladiile, Bosa and Nkele, Isaac and Chinyepi, Nkhabe and Makhema, Moeketsi J and Friebel-Klingner, Tara M and Vuylsteke, Peter and Lockman, Shahin and Dryden-Peterson, Scott and Kohler, Racquel E},
title = {Access to and Utilization of Endocrine Therapy Among Breast Cancer Survivors in Botswana},
journal = {JCO Global Oncology},
year = {2024},
doi = {10.1200/go.24.00180}
}
EUVIMED